Mallinckrodt Pharmaceuticals today commended Missouri Gov. Eric Greitens for his executive order to establish an innovative Prescription Drug Monitoring Program (PDMP) in Missouri, which will bring Missouri closer to having an essential tool for fighting opioid misuse, abuse, and addiction. Prior to this order, Missouri was the only state without a PDMP.
“We applaud the first steps Governor Greitens has taken to make a common sense, patient-focused PDMP a reality in a state we have called home for 150 years,” said Mark Trudeau, Mallinckrodt President and CEO. “As a manufacturer, Mallinckrodt is dedicated to providing safe and effective medications for patients and has worked with partners like Rep. Holly Rehder (148-Cape Girardeau) for years to enact a PDMP.
“Without Rep. Rehder's commitment and herculean efforts in the trenches year after year, this announcement today would not be possible,” said Trudeau. “We thank Gov. Greitens for his action and urge him to ensure that the County PDMP mandatory programs work in tandem with this innovative approach, providing all stakeholders the tools they need to combat our state’s opioid epidemic.”
Trudeau concluded, “We look forward to working with patient groups, policymakers, law enforcement and industry to help implement the Governor’s order in a manner that addresses the complex issues of opioid misuse and abuse.”
A fully implemented PDMP supports prescribers and can help prevent abuse by providing timely data for the treatment of patients. These programs help identify illicit activities such as using duplicate prescriptions while visiting multiple doctors, something called “doctor shopping.” Evidence shows PDMPs also lead to better health outcomes, shorten the time needed to conduct law enforcement investigations, and lower overall abuse and diversion rates. Having a robust PDMP in every state is a primary recommendation of the U.S. Centers for Disease Control and Prevention to reduce abuse of pain medications.
Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and hemostasis products. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.
Senior Communications Manager
Chief Public Affairs Officer
Coleman N. Lannum, CFA
Senior Vice President, Investor Strategy and IRO
Daniel J. Speciale, CPA
Director, Investor Relations